Cencora, Inc. $COR Holdings Raised by Premier Path Wealth Partners LLC

Premier Path Wealth Partners LLC grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 5.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,379 shares of the company’s stock after purchasing an additional 73 shares during the period. Premier Path Wealth Partners LLC’s holdings in Cencora were worth $413,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of COR. Voleon Capital Management LP bought a new position in shares of Cencora during the first quarter worth about $3,111,000. Focus Partners Wealth boosted its stake in Cencora by 25.8% during the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after purchasing an additional 1,171 shares during the period. Martin Capital Partners LLC grew its position in Cencora by 205.2% in the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after purchasing an additional 2,544 shares during the last quarter. Fiduciary Alliance LLC bought a new position in Cencora in the 2nd quarter worth about $262,000. Finally, Ascent Group LLC increased its stake in shares of Cencora by 42.7% in the first quarter. Ascent Group LLC now owns 12,586 shares of the company’s stock valued at $3,500,000 after purchasing an additional 3,764 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Down 1.1%

Shares of Cencora stock opened at $337.60 on Friday. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The company has a market cap of $65.45 billion, a P/E ratio of 34.73, a P/E/G ratio of 1.56 and a beta of 0.63. The stock has a 50-day moving average price of $308.09 and a 200 day moving average price of $297.02. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $350.46.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $80.66 billion during the quarter, compared to analyst estimates of $80.34 billion. During the same period last year, the company earned $3.34 earnings per share. Cencora’s quarterly revenue was up 8.7% compared to the same quarter last year. As a group, analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s dividend payout ratio (DPR) is 22.63%.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 41,544 shares of company stock worth $12,230,941. Insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

COR has been the topic of several analyst reports. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Morgan Stanley set a $330.00 price target on Cencora and gave the company an “equal weight” rating in a report on Wednesday, July 16th. Evercore ISI set a $340.00 price objective on shares of Cencora in a research note on Wednesday, October 8th. UBS Group increased their target price on shares of Cencora from $350.00 to $380.00 and gave the company a “buy” rating in a research report on Monday. Finally, Mizuho boosted their price target on shares of Cencora from $334.00 to $340.00 and gave the stock an “outperform” rating in a research report on Thursday. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $329.55.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.